Navigation Links
PROMACTA(R) (eltrombopag) RECEIVES UNANIMOUS RECOMMENDATION BY FDA ADVISORY PANEL
Date:5/30/2008

n, affecting less than 200,000 individuals in the United States.(1)

Eltrombopag is an investigational, once-daily oral treatment developed to induce the production of cells in the bone marrow to increase platelets, which are critical in minimizing the incidence of bleeding in chronic ITP.

Eltrombopag, a novel oral thrombopoeitin (TPO) receptor agonist, if approved, would be the first oral short-term treatment of previously treated patients with chronic ITP to increase platelet counts and reduce or prevent bleeding.

In the pivotal studies, the most common adverse events observed in patients taking eltrombopag were headache, nasopharyngitis, and nausea.

About the data

The NDA submission is supported by the largest database of clinical trial information on investigational therapies for chronic ITP patients. Two pivotal trials (one Phase III trial and one Phase II trial), were submitted to support the filing.

About ITP

Chronic ITP is a disorder marked by increased platelet destruction and/or inadequate platelet production in the blood, which causes an increased risk of bruising and bleeding.(2,3) There are estimated to be approximately 60,000 individuals diagnosed with chronic ITP in the U.S.(4) People with chronic ITP often bleed from small blood vessels causing bruises, nosebleeds or even fatal gastrointestinal or intra cerebral bleeds, although these are rare.(3)

About Eltrombopag

Eltrombopag is an oral, non-peptide thrombopoietin receptor agonist that has been shown in pre-clinical research and clinical trials to stimulate the proliferation and differentiation of megakaryocytes, the bone marrow cells that give rise to blood platelets. Eltrombopag was discovered as a result of research collaboration between GlaxoSmithKline and Ligand Pharmaceuticals (Nasdaq:

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. GlaxoSmithKline Files for FDA Approval of PROMACTA(TM) (eltrombopag) to be the First Oral Platelet Growth Factor for Rare Blood Disorder
2. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
3. DaVita Receives Civil Complaint
4. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
5. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
6. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
7. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
8. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
9. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
10. Prime Therapeutics Receives TIPPS Certification
11. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Camden, NJ (PRWEB) July 28, 2014 ... to provide enhanced access and reduced wait times for ... only six hospital systems in the state—and the only ... HealthNet Federal Services Patient-Centered Community Care program (PC3). PC3 ... Veterans Administration (VA) hospital cannot provide services due to ...
(Date:7/28/2014)... near green spaces deliver babies with significantly higher ... Spaces and Adverse Pregnancy Outcomes" published in the ... A team of researchers from Israel and Spain, ... nearly 40,000 single live births from a registry ... the impact of green surroundings during pregnancy and ...
(Date:7/28/2014)... Drorit Silverman, a professional bodybuilder and chiropractor ... investment capital through her crowd funding camping to tap ... States. , According to a statement released by Drorit ... a great window of opportunity for investors like her ... to this, Silverman looks at the 24/7 fitness concept ...
(Date:7/28/2014)... July 28, 2014 Qualis Health, ... care management organizations, has published a complimentary, online ... to engaging patients and families in infection control. ... multiple hospitals, the toolkit provides a step-by-step roadmap ... patients and their families early in a hospital ...
(Date:7/28/2014)... MONDAY, July 28, 2014 (HealthDay News) -- A ... stiffness in older people may increase the risk ... suggests. A British study found that patients ... vascular disease -- conditions that affect the blood ... factors of patients with polymyalgia rheumatica to reduce ...
Breaking Medicine News(10 mins):Health News:Lourdes Expands Military Partnership with Veterans 2Health News:Lourdes Expands Military Partnership with Veterans 3Health News:Pro Bodybuilder Drorit Silverman Confirms Plans to Raise Money for Investment in the Popular 24/7 Fitness Concept 2Health News:Patient Engagement in Hospital Infection Control: Online Toolkit Provides a New Solution 2Health News:Inflammatory Muscle Disorder May Raise Risk for Heart Attack, Stroke 2
... March 24 Avidas(TM) Pharmaceuticals, a privately held, ... women,s health, today announced the launch of Scalacort(TM) ... in one patient convenience kit.Scalacort DK includes Scalacort ... in a clear fragrance-free base. Scalacort relieves itching ...
... since the 1994 federal health reform debate is chronicled ... Week,PRINCETON, N.J., March 24 With Congress and the ... care system, a new report looks at what has ... 1994 without any comprehensive congressional action. The analysis from ...
... Syndromic Surveillance CapabilitiesSAN DIEGO, March 24 Crossflo ... Board: PTSC) an innovative provider of data-sharing solutions ... focused on implementing a data sharing system for ... State of Montana. The Crossflo DataExchange(R) Server ...
... Arizona Attorney General,s Office has opened an investigation ... Action released videos with undercover footage from three ... two Planned Parenthood clinics in Phoenix, AZ and ... laws for sexual abuse, and offering secret abortions ...
... call for better measurement and transparency as foundation for ... a diverse coalition of more than 165 organizations from ... to improve the quality and affordability of health care ... six key recommendations.The six recommendations are: , , ...
... are bringing more than May flowers. April Rain® is springing to ... their brand new product, Day Rainew®. April Rain® is lighting up ... skin solution to battle extreme stressors and any environmental factors. , ... ...
Cached Medicine News:Health News:Avidas(TM) Pharmaceuticals Introduces Scalacort(TM) DK Which Offers Three Scalp Solutions in One Patient Convenience Kit 2Health News:Avidas(TM) Pharmaceuticals Introduces Scalacort(TM) DK Which Offers Three Scalp Solutions in One Patient Convenience Kit 3Health News:More Working People Go Without Health Coverage as Insurance Costs Outpace Income 2Health News:More Working People Go Without Health Coverage as Insurance Costs Outpace Income 3Health News:More Working People Go Without Health Coverage as Insurance Costs Outpace Income 4Health News:Crossflo Provides Data Sharing for Montana Health Information Exchange 2Health News:Crossflo Provides Data Sharing for Montana Health Information Exchange 3Health News:Arizona Attorney General to Investigate Sexual Abuse Cover Up at Planned Parenthood Clinics 2Health News:Broad Coalition Offers Plan to Improve Health Care Quality and Affordability 2Health News:Broad Coalition Offers Plan to Improve Health Care Quality and Affordability 3Health News:April Rain is Protecting Skin with The Launch of Day Rainew 2Health News:April Rain is Protecting Skin with The Launch of Day Rainew 3
(Date:7/28/2014)... -- Concord Medical Services Holdings Limited ("Concord Medical" or ... specialty hospital management solution provider and operator of the ... China , today announced that on ... special cash dividend of US$0.30 per ordinary share (or ... outstanding ordinary shares. The total expense for the special ...
(Date:7/28/2014)... TOKYO , July 28, 2014 /PRNewswire/ ... appointed Roger Crystal , MD as Vice President ... the Global Business Development Product Acquisition & Licensing team ... in developing business strategy and partnerships in the precision ... to partner with biotechnology and pharmaceutical companies across the ...
(Date:7/28/2014)... , July 28, 2014   Cardioxyl Pharmaceuticals, ... clinical trial demonstrating that CXL-1427, a novel potential treatment ... in healthy volunteers. The company has now initiated dosing ... Phase IIa clinical trial designed to further evaluate the ... levels. The Phase I clinical trial evaluated ...
Breaking Medicine Technology:Concord Medical Declares Special Dividend 2ImaginAb Appoints Roger Crystal, MD as Vice President of Business Development 2Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 2
... , CHICAGO , July 30 ... equity firm focused exclusively on health care, announced today ... (MSD).  Headquartered in Stoughton, Massachusetts , MSD ... biomedical services and technology solutions to the growing home ...
... , CATANIA, Italy , July 30 ... European research project today announced details of the ... three-year ENIAC (European Nanoelectronics Initiative Advisory Council) project ... 3D-imaging platforms by focusing on the diagnosis and ...
Cached Medicine Technology:Water Street Healthcare Partners Announces New Investment in Medical Specialties Distributors, LLC 2Water Street Healthcare Partners Announces New Investment in Medical Specialties Distributors, LLC 3Water Street Healthcare Partners Announces New Investment in Medical Specialties Distributors, LLC 4European Research Project Aims to Improve the Diagnosis and Therapy of Brain Diseases 2European Research Project Aims to Improve the Diagnosis and Therapy of Brain Diseases 3
The MPF cup is specifically designed to achieve high primary stability, a critical factor for long term success....
The cementless biomEx cup can be used with both cemented and cementless femoral stems....
Trident Hemispherical Acetabular Shells are a true hemispherical shape designed to achieve press-fit fixation by under-reaming the acetabulum....
For primary and revision cases...
Medicine Products: